Occult primary, version 3.2014; Featured updates to the NCCN guidelines

David S. Ettinger, Charles R. Handorf, Mark Agulnik, Daniel W. Bowles, Justin M. Cates, Mihaela Cristea, Efrat Dotan, Keith D. Eaton, Panagiotis M. Fidias, David Gierada, G. Weldon Gilcrease, Kelly Godby, Renuka Iyer, Renato Lenzi, John Phay, Asif Rashid, Leonard Saltz, Richard B. Schwab, Lawrence N. Shulman, Jeffrey B. SmerageMarvaretta M. Stevenson, Gauri R. Varadhachary, Jonathan S. Zager, Weining Zhen, Mary Anne Bergman, Deborah A. Freedman-Cass

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.

Original languageEnglish (US)
Pages (from-to)969-974
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2014

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Occult primary, version 3.2014; Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this